tbuckley/cabot-search huggingface dataset:
Prenatal diagnosis in a subset of trichothiodystrophy patients defective in DNA repair
Authors: A. SARASIN, C. BLANCHET-BARDON, G. RENAULT, A. LEHMANN, C. ARLETT, Y. DUMEZ
Journal: British Journal of Dermatology (1992)

Journal Article Prenatal diagnosis in a subset of trichothiodystrophy patients defective in DNA repair Get access A. SARASIN, A. SARASIN Laboratory of Molecular Genetics, Institut de Recherches Scientifiques sur le Cancer, B.P. No 8, 94801 Villejuif Cedex, France Dr A.Sarasin, laboratory of Molecular Genetics, Institut de Recherches Scientifiques sur le Cancer, B.P. No 8, 94801 Villejuif Cedex, France. Search for other works by this author on: Oxford Academic Google Scholar C. BLANCHET‐BARDON, C. BLANCHET‐BARDON Laboratory of Molecular Genetics, Institut de Recherches Scientifiques sur le Cancer, B.P. No 8, 94801 Villejuif Cedex, FranceCliniques des maladies cutanées (Prof. L. Dubertret). Hôpital Saint‐Louis, 75010 Paris, France Search for other works by this author on: Oxford Academic Google Scholar G. RENAULT, G. RENAULT Laboratory of Molecular Genetics, Institut de Recherches Scientifiques sur le Cancer, B.P. No 8, 94801 Villejuif Cedex, France Search for other works by this author on: Oxford Academic Google Scholar A. LEHMANN, A. LEHMANN MRC Cell Mutation Unit, University of Sussex, Falmer, Brighton BNI 9RR, U.K. Search for other works by this author on: Oxford Academic Google Scholar C. ARLETT, C. ARLETT MRC Cell Mutation Unit, University of Sussex, Falmer, Brighton BNI 9RR, U.K. Search for other works by this author on: Oxford Academic Google Scholar Y. DUMEZ Y. DUMEZ Maternité Port‐Royal, Hospital de Port‐Royal, 75005 Paris, France Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 127, Issue 5, 1 November 1992, Pages 485–491, https://doi.org/10.1111/j.1365-2133.1992.tb14845.x Published: 01 November 1992
Lactic Acidosis and AIDS
Authors: Thomas Coyle
Journal: Annals of Internal Medicine (1993)

Letters15 August 1993Lactic Acidosis and AIDSThomas Coyle and Eleanor AbelThomas CoyleSearch for more papers by this author and Eleanor AbelSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-4-199308150-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Chattha and colleagues [1] recently reported seven patients with AIDS who had type B lactic acidosis without other obvious causes. We report an additional case of unexplained lactic acidosis in a 25-year-old, HIV-infected patient with hemophilia. He had been receiving zidovudine for 10 months, had a CD4 count ranging from 230/L to 160/L, and had been symptomatic with ophthalmic herpes zoster 2 years before. He had a hepatitis C infection and mild chronic elevations of his transaminase levels. His symptoms in June 1990 were anorexia, hyperventilation, and weight loss, and he was found to have lactic acidosis ...REFERENCE1. Chattha G, Arieff AI, Cummings C, Tierney LM Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med. 1993; 118:37-9. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLactic acidosis related to nucleoside therapy in HIV-infected patientsSevere Nucleoside-Associated Lactic Acidosis in Human Immunodeficiency Virus–Infected Patients: Report of 12 Cases and Review of the LiteratureLactic Acidosis Associated with Nucleoside Analog Therapy in an HIV-Positive PatientThe Chemical Pathology of AIDS 15 August 1993Volume 119, Issue 4Page: 343-345KeywordsAIDSHIV infectionsHepatitis ALactic acidosisLiver diseasesLiver function testsMusclesSerum glutamic oxaloacetic transaminaseUric acidWeight loss ePublished: 15 August 2000 Issue Published: 15 August 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
REHABILITATION AND PREHABILITATION
Authors: LEONARD G. ROWNTREE
Journal: JAMA (1942)

Selective Service appreciates the privilege of discussing with the American Medical Association, through the Section on Preventive and Industrial Medicine and Public Health, the subject of rehabilitation. This is a matter of considerable national importance at the present time. Perhaps the subject can be best approached by referring to the third statistical survey carried out by Selective Service and appearing as Medical Statistics Bulletin No. 1. This affords a basis for discussion and perhaps for action. It indicates that, of the 2,000,000 men examined up to May 31, 1941, 1,000,000 were rejected by the examining boards of Selective Service and the Army. The breakdown according to symptoms is given in table 1. This must not be interpreted as indicating 50 per cent invalidism or sickness of registrants or as indicating 50 per cent crippling of the total population of the country. The survey does, however, reveal a high incidence of
Studies on an Attenuated Measles-Virus Vaccine
Authors: Martha Lipson Lepow, Nigel Gray, Frederick C. Robbins
Journal: New England Journal of Medicine (1960)

THIS study discusses the clinical, antigenic and prophylactic effects of the measles vaccine in a group of institutionalized and home-dwelling children in Cleveland.Plan of StudyVaccine Employed and Method of AdministrationAliquots of lots 136E (vaccine A) and 913D (vaccine B) were used in the present study. The method of production of these vaccines has previously been described. The vaccine was kept at -60°C. in 1-ml. ampoules until used. All subjects received 0.5 ml. of vaccine subcutaneously in the upper arm.Laboratory MethodsComplement-fixing-antibody titers were determined on all serums according to the micro method of Fulton and Dumbell. . . .
Thresholds, dose-response relationships and dose metrics in allergic contact dermatitis
Authors: I. Kimber, D. Basketter
Journal: British Journal of Dermatology (2008)

Conflicts of interest: none declared. Sir, In his recent article Professor Peter Friedmann reviewed what we have learned about thresholds, dose–response relationships and dose metrics in allergic contact dermatitis.1 This was an excellent, timely and comprehensive survey which maps out our understanding of the relationships that exist between exposure to chemical allergens and the acquisition of skin sensitization. However, in his concluding comments Professor Friedmann made an assertion that we would like to explore and challenge. He wrote: ‘The fact that there are individuals who respond to various contact sensitizers, mainly fragrance ingredients and preservatives, at the level of 5–10 p.p.m. indicates that they are sensitized to a high degree. There are two possible explanations for this: firstly, that these are exceptional ‘high responders’ who are sensitized by chemicals to which most people do not react; secondly, as the relevant sensitizers can induce such strong sensitization when they are normally encountered at low levels in personal products, this indicates that they are actually potent sensitizers. Furthermore, because the exposure concentration is low, it implies that repeated exposures to such low concentrations can still induce high degrees of sensitivity. Therefore future work should concentrate on two main areas: one is defining the dose–response relationships for sensitization by repeated applications of very low doses of antigen. The other is investigation of the effects of different times of application of elicitation challenge under both open and occluded conditions.1
Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4
Authors: Kyoko Ochiai, Mark Maienschein-Cline, Giorgia Simonetti, Jianjun Chen, Rebecca Rosenthal, Robert Brink, Anita S. Chong, Ulf Klein, Aaron R. Dinner, Harinder Singh, Roger Sciammas
Journal: Immunity (2013)
Association of systemic psoriasis therapies and incidence of myocardial infarction: reply from authors
Authors: K. Abuabara, H. Lee, A.B. Kimball
Journal: British Journal of Dermatology (2011)

Funding sources: The investigators received a physician‐initiated grant from Abbott, Inc. to support this work and to gain access to the UnitedHealth data. The design and conduct of the study, data management, analysis and interpretation, and preparation and approval of the manuscript were all performed independently by the investigators. This work was also funded by the American Academy of Dermatology’s Minority Student Mentorship Program. Conflicts of interest: K.A. and H.L., none declared. A.B.K., Investigator and Consultant for Abbott, Centocor and Amgen. She has an outcomes fellowship supported by Centocor. Her department administers phototherapy. Madam, We appreciate the comments by Wu et al.1 and the opportunity to elaborate on several important concepts and methodological strategies key for this kind of observational research. The first issue is defining the treatment groups. We agree, as noted in the introduction to our study,2 that nearly all of the treatments for moderate‐to‐severe psoriasis could increase cardiovascular risk. To ensure that combining medications with different mechanisms of action in our analysis did not mask pleiotropic effects, we ran the models first by individual treatment category and then with all treatments excluding patients receiving each treatment category one at a time. These analyses did not result in any significant change in our results. We intentionally did not include patients receiving only psoralen + ultraviolet (UV) A (PUVA) or acitretin in our published data because they did not fit into the hypothesis we were testing: PUVA may be systemically immunomodulatory and therefore we did not want to include it with UVB, and acitretin may worsen lipid profiles and is not thought to be immunosuppressive, although it may be immunomodulatory. None the less, in sensitivity analyses not reported in the original manuscript due to space constraints, including patients receiving these treatments in the ‘systemic therapies’ group produced nearly identical results.
An Annotated Bibliography of the History of Medicine and Health in Australia
Authors: Micaela Sullivan
Journal: JAMA (1985)

Although annotated bibliographies are nothing new, exceptional ones exist; Gandevia's bibliography is such an example. The goal was to publish a work that would supersede, as well as incorporate, the earlier<i>An Annotated Bibliography of the History of Medicine in Australia</i>(1957). All but a few of the entries from the 1957 edition have been retained, although the annotations have been reviewed and revised, if appropriate. The inclusion of social history of medicine sources and a greater emphasis on the history of preventive medicine and environmental aspects of diseases make this new version more comprehensive than its predecessor. Journal references beginning about 1897 and ending in mid-1983 constitute the majority of the citations. It seems that few texts have been written on the history of medicine in Australia. The work is divided into 19 chapters or thematic subject areas, including such titles as "Medical Aspects of the Discovery and Exploration
Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis
Authors: Clare L Gillies, Paul C Lambert, Keith R Abrams, Alex J Sutton, Nicola J Cooper, Ron T Hsu, Melanie J Davies, Kamlesh Khunti
Journal: BMJ (2008)

<b>Objective</b> To compare four potential screening strategies, and subsequent interventions, for the prevention and treatment of type 2 diabetes: (<i>a</i>) screening for type 2 diabetes to enable early detection and treatment, (<i>b</i>) screening for type 2 diabetes and impaired glucose tolerance, intervening with lifestyle interventions in those with a diagnosis of impaired glucose tolerance to delay or prevent diabetes, (<i>c</i>) as for (<i>b</i>) but with pharmacological interventions, and (<i>d</i>) no screening. <b>Design</b> Cost effectiveness analysis based on development and evaluation of probabilistic, comprehensive economic decision analytic model, from screening to death. <b>Setting</b> A hypothetical population, aged 45 at time of screening, with above average risk of diabetes. <b>Data sources</b> Published clinical trials and epidemiological studies retrieved from electronic bibliographic databases; supplementary data obtained from the Department of Health statistics for England and Wales, the screening those at risk (STAR) study, and the Leicester division of the ADDITION study. <b>Methods</b> A hybrid decision tree/Markov model was developed to simulate the long term effects of each screening strategy, in terms of both clinical and cost effectiveness outcomes. The base case model assumed a 50 year time horizon with discounting of both costs and benefits at 3.5%. Sensitivity analyses were carried out to investigate assumptions of the model and to identify which model inputs had most impact on the results. <b>Results</b> Estimated costs for each quality adjusted life year (QALY) gained (discounted at 3.5% a year for both costs and benefits) were £14 150 (€17 560; $27 860) for screening for type 2 diabetes, £6242 for screening for diabetes and impaired glucose tolerance followed by lifestyle interventions, and £7023 for screening for diabetes and impaired glucose tolerance followed by pharmacological interventions, all compared with no screening. At a willingness-to-pay threshold of £20 000 the probability of the intervention being cost effective was 49%, 93%, and 85% for each of the active screening strategies respectively. <b>Conclusions</b> Screening for type 2 diabetes and impaired glucose tolerance, with appropriate intervention for those with impaired glucose tolerance, in an above average risk population aged 45, seems to be cost effective. The cost effectiveness of a policy of screening for diabetes alone, which offered no intervention to those with impaired glucose tolerance, is still uncertain.
JAMA's New Look
Authors: Annette Flanagin
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in Mice
Authors: Tracy E. Strecker, Qiang Shen, Yun Zhang, Jamal L. Hill, Yuxin Li, Chunyu Wang, Hee-Tae Kim, Tona M. Gilmer, Krystal R. Sexton, Susan G. Hilsenbeck, C. Kent Osborne, Powel H. Brown
Journal: JNCI Journal of the National Cancer Institute (2009)

Lapatinib, a selective orally available inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 receptor tyrosine kinases, is a promising agent for the treatment of breast cancer. We examined the effect of lapatinib on the development of mammary tumors in MMTV-erbB2 transgenic mice, which express wild-type ErbB2 under the control of the mouse mammary tumor virus promoter and spontaneously develop estrogen receptor (ER)-negative and ErbB2-positive mammary tumors by 14 months of age. Mice were treated from age 3 months to age 15 months with vehicle (n = 17) or lapatinib (30 or 75 mg/kg body weight; n = 16 mice per group) by oral gavage twice daily (6 d/wk). All statistical tests were two-sided. By 328 days after the start of treatment, all 17 (100%) of the vehicle-treated mice vs five (31%) of the 16 mice treated with high-dose lapatinib developed mammary tumors (P < .001). Among MMTV-erbB2 mice treated for 5 months (n = 20 mice per group), those treated with lapatinib had fewer premalignant lesions and noninvasive cancers in their mammary glands than those treated with vehicle (P = .02). Lapatinib also effectively blocked epidermal growth factor-induced signaling through the EGFR and ErbB2 receptors, suppressed cyclin D1 and epiregulin mRNA expression, and stimulated p27 mRNA expression in human mammary epithelial cells and in mammary epithelial cells from mice treated for 5 months with high-dose lapatinib. Thus, cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinib response in patients. These data suggest that lapatinib is a promising agent for the prevention of ER-negative breast cancer.
Abstract P5-07-09: An aberrant spliced transcript of focal adhesion kinase expressed in human breast cancer
Authors: L Yao, W Peng, S Li, Z Shao
Journal: Cancer Research (2013)

Abstract Background: Focal adhesion kinase is a tyrosine kinase that plays a critical role at focal adhesion sites in cell mobility and migration. The over-expression and mutation of FAK, which promotes tumor cell invasion and survival, frequently occurs in tumors, allowing FAK to be recognized as a cancer-relevant gene and a potential target for cancer treatment. The vast majority of evidence has revealed that the deregulation of alternative splicing processes often occurs in cancer-associated genes and leads to tumorigenesis. Results: From 102 breast cancer tissue samples, we found six samples contained the 26 exon deletion FAK associated with a mutation at the 3192 bp site(CDS), but this 26 exon deletion FAK was not observed in the samples derived from 101 normal tissues. Interestingly, the 26 exon deletion FAK, which possesses the same kinase activity and biological function as wild-type FAK, is resistant to caspase-mediated cleavage and prevents breast cancer cells from apoptosis, promoting breast cancer cells survival. Conclusion: Therefore, our study revealed that the aberrant splicing of the FAK gene may promote tumorigenesis, providing a new method for diagnosing breast cancer and a potentially important target for breast cancer treatment. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-07-09.
Non-Q-Wave Myocardial Infarction
Authors: J. Ward Kennedy
Journal: New England Journal of Medicine (1986)

This issue of the Journal contains two important papers on non-Q-wave myocardial infarction.1 , 2 The rapid evolution of therapy for Q-wave myocardial infarction with the increasing use of thrombolytic procedures and early coronary angioplasty makes this a good time to reevaluate the pathophysiologic aspects of non-Q-wave infarction and the treatment of this condition.In recent years, there has been abundant editorial comment about nontransmural and transmural myocardial infarctions and the relation between the pathological findings in these conditions and the presence of abnormal Q waves on the surface electrocardiogram.3 , 4 Although some disagreement may still exist, I believe that several points are . . .
Malaria deaths in India have been underestimated, new study indicates
Authors: G. Mudur
Journal: BMJ (2010)

A nationwide mortality survey in India has indicated that the World Health Organization’s estimates of malaria mortality are too low. But the methods of the new study, which used “verbal autopsies” to assign the cause of death, have been criticised by WHO. 

The study, published on Thursday 21 October, says that malaria may be causing about 200 000 deaths a year in India among people below the age of 70 ( Lancet doi:10.1016/S0140-6736(10)60831-8). This figure is much higher than WHO’s upper estimate of 21 000 deaths from malaria in 2006.

The survey was part of India’s million death study, which seeks to assign causes of deaths in 1.1 million homes through “verbal autopsies,” whereby two doctors attribute a probable cause of death after a scrutiny of the symptoms …
P3-019: Serum Cathepsin B (CB) is prognostic and may predict response to therapy in chemotherapy-naive PS2 advanced NSCLC patients treated on two concurrent phase III trials of paclitaxel poliglumex (PPX) vs control treatments (STELLAR 3 and 4)
Authors: Helen J. Ross, Fred Oldham, B Bandstra, L Salindac, Philip Bonomi, Jack Singer
Journal: Journal of Thoracic Oncology (2007)
Bone Marrow–Derived Stromal Cells Express Lineage-Related Messenger RNA Species
Authors: Natalie C. Direkze, Rosemary Jeffery, Kairbaan Hodivala-Dilke, Toby Hunt, Raymond J. Playford, George Elia, Richard Poulsom, Nicholas A. Wright, Malcolm R. Alison
Journal: Cancer Research (2006)

Abstract Evidence has emerged that bone marrow cells have a greater degree of plasticity than previously thought. However, there has been a call to establish proof that these bone marrow–derived cells function appropriately in their new environment. We have already shown that the bone marrow contributes to myofibroblasts in multiple organs and that this is exacerbated by injury and occurs in a mouse tumor model. Here, we provide evidence that these cells are functioning appropriately by showing that bone marrow–derived myofibroblasts are expressing mRNA for the α1 chain of type I (pro)collagen using a new customized technique. This provides evidence that the bone marrow-tumor stroma axis is functionally relevant and may therefore subsequently be exploited to develop new strategies for anticancer therapy. (Cancer Res 2006; 66(3): 1265-9)
FDA Ponders Regulation and Innovation
Authors: Rebecca Voelker
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal